AMGNAmgen

$440.34

$265.4052 weeks$443.80

Price

$440.34+59%1Y

1M+19%1Y+59%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value49

Quality95

Momentum61

Growth47

Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies.

In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR

P/E (TTM)27.4

Market Cap$182.21B

1Y Return+59%

5Y Return+113%

Business segments

Q2 2026 · $7.51B

The company’s own SEC segment disclosure.

Other Products$1.28B17%
Enbrel$574.0M8%
EVENITY$550.0M7%
TEPEZZA$520.0M7%
Product And Service Other$517.0M7%
Repathaevolocumab$510.0M7%
Other (12)$3.55B47%

Amgen (AMGN) reported revenue of $10.1B in Q2 2026 (quarter ended June 30, 2026), up 9.5% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $2.38B (24% of revenue). For the full year FY2025, revenue was $36.8B (+10.0% year on year) and net income $7.71B. Its largest product in 2026-Q2 was Other Products at $1.28B, 17% of the disclosed total, just ahead of Enbrel at 7.6%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - General

Ranks #5 of 16 by Smart Score